Technology Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences Business Wire Apr 17, 2023 PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’…